PDF icon PDF herunterladen
Open Access
CC BY 4.0 · Chinese medicine and natural products 2022; 02(03): e152-e157
DOI: 10.1055/s-0042-1757462
Original Article

Clinical Effects of Bushen Culuan Prescription on Infertility Due to Decreased Ovarian Reserve of Kidney Deficiency and Liver Depression Pattern

Yanqi Feng
1   Teaching and Research Department of Gynecology and Obstetrics, Henan Medical College, Zhengzhou, Henan, China
,
Sujuan Ma
2   Department of Obstetrics and Gynecology, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China
› Institutsangaben
Funding None.
› Weitere Informationen
Auch verfügbar aufeRef
  Lizenzen und Reprints
Preview

Abstract

Objective The objective of this study was to explore the clinical effects of Bushen Culuan prescription on infertility due to decreased ovarian reserve of kidney deficiency and liver depression pattern.

Methods Totally 100 infertile patients with ovarian hypofunction treated from October 2019 to January 2022 were selected and divided into the observation group and the control group by a random number table. The control group was treated with estrogen sequential therapy, and the observation group was treated with Bushen Culuan prescription. The clinical efficacy, sex hormone levels including (follicle-stimulating hormone [FSH], luteinizing hormone [LH], and estradiol [E2]), ovarian function, ovarian blood flow status (peak systolic velocity [PSV], antral follicle count [AFC], arterial pulse index [PI], and resistance index [RI]), and pregnancy outcome in the two groups were compared and analyzed.

Results The total effective rate of the observation group (96.00%) was significantly higher than that of the control group (80.00%). The difference was statistically significant (p < 0.05). Before treatment, there was no significant difference in sex hormone levels (FSH, LH, E2, and FSH/LH), ovarian function (number of primary follicles, number of dominant follicles, ovulation number, and endometrial thickness), and ovarian blood flow (PSV, RI, PI, and AFC) between the two groups (p > 0.05). After treatment, the levels of serum hormones FSH, LH, E2, and FSH/LH decreased significantly in both groups. The number of primary follicles, dominant follicles, and ovulation increased significantly, and the thickness of endometrium decreased significantly; the indexes of PSV, RI, and AFC of ovarian blood flow increased significantly, and the PI index decreased significantly. The levels of each index in the observation group were better than those in the control group (p < 0.05). In the control group, 32 cases were pregnant within 1 year after treatment, and the pregnancy rate was 64.00%; 21 cases in the observation group were pregnant within 1 year after treatment, and the pregnancy rate was 42.00%; the pregnancy rate in the observation group was higher than that in the control group, and the difference was statistically significant (χ2 = 4.014, p = 0.045 < 0.05).

Conclusion Bushen Culuan prescription has a definite effect on infertility due to ovarian hypofunction. The action mechanism may involve multicomponent and multitarget stimulation to improve patients' ovarian function, regulate the level of sex hormones, and improve the pregnancy outcome.

Keywords

infertility - Bushen Culuan prescription - ovarian hypofunction - estrogen sequential therapy

CRediT Authorship Contribution Statement

Yanqi Feng: Conceptualization, funding acquisition, supervision, writing -original draft. Sujuan Ma: Investigation, methodology, validation, writing-review & editing.




Publikationsverlauf

Eingereicht: 21. März 2022

Angenommen: 02. Mai 2022

Artikel online veröffentlicht:
27. Oktober 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Li J, Xu L, Gao Y. Research progress and status quo of pathogenesis and treatment of premature ovarian failure. China Med Pharm 2021; 11 (02) 58-61
    Suche in Google Scholar
  • 2 Qiao Z, Yang R, Xu HJ. et al. Observation of the curative effects of recombinant human growth hormone combined with different ovulation induction modes. Mod J Integr Tradit Chin West Med 2018; 27 (02) 180-182
    Suche in Google Scholar
  • 3 Chen SY, Gao J, Du X. et al. Study on medication rules of TCM in treating premature ovarian failure based on data mining. Henan Tradit Chin Med 2018; 38 (07) 1104-1108
    Suche in Google Scholar
  • 4 Li SQ. Effect of human menopausal conadotropin combined with letrozole on endometrial thickness and pregnancy outcome in patients with polycystic ovary syndrome-induced infertility. Chin J Ration Drug Use 2018; 15 (09) 22-24
    Suche in Google Scholar
  • 5 Liu S, Bao LL, Feng XY. et al. The clinical outcomes of modified natural-cycle for ageing women with poor ovarian responder during IVF-ET. J Int Reproductive Heal Plan 2018; 37 (04) 281-284
    Suche in Google Scholar
  • 6 Gong S. Effects of recombinant human growth hormone combined with double stimulation ovulation induction on ovarian functions in sterile patients with ovarian dysfunction. Chin J Ration Drug Use 2019; 16 (05) 149-152
    Suche in Google Scholar
  • 7 Kristensen SG, Pors SE, Andersen CY. Improving oocyte quality by transfer of autologous mitochondria from fully grown oocytes. Hum Reprod 2017; 32 (04) 725-732
    PubMedSuche in Google Scholar
  • 8 Tachibana M, Kuno T, Yaegashi N. Mitochondrial replacement therapy and assisted reproductive technology: a paradigm shift toward treatment of genetic diseases in gametes or in early embryos. Reprod Med Biol 2018; 17 (04) 421-433
    CrossrefPubMedSuche in Google Scholar
  • 9 Menopause Group of Gynecology and Obstetrics Branch of Chinese Medical Association. Specialists consensus on hormone supplementary treatment for early-onset hypoovarianism. Zhonghua Fu Chan Ke Za Zhi 2016; 51 (12) 881-886
    PubMedSuche in Google Scholar
  • 10 Ministry of Health of the People's Republic of China. Guiding Principles for clinical research of new Chinese Materia Medica. Beijing: China Medical And Technology Press; 1993: 276-280
    Suche in Google Scholar
  • 11 Lv AX, Qin HP, Mo SK. et al. Clinical study on ovulation induction after pretreatment of dehydroepiandrosterone in patients with diminished ovarian reserve. J Reprod Med 2022; 31 (01) 58-62
    Suche in Google Scholar
  • 12 Wang H, Bai SF. Clinical study of Bushen-Tiaojing decoction combined with estrogen and progesterone replacement therapy in the treatment of premature ovarian failure. Int J Tradit Chin Med 2020; 42 (10) 960-963
    Suche in Google Scholar
  • 13 Wang JY, Sun L, Yang L. Effects of dehydroepiandrosterone on sex hormones and pregnancy rate in patients with diminished ovarian reserve dysfunction. Contemp Med 2021; 27 (02) 68-70
    Suche in Google Scholar
  • 14 Li RX, Zhang Y. Discussion about treating anovulatory infertility caused by polycystic ovary syndrome by soothing the liver and nourishing the heart. Henan Tradit Chin Med 2021; 41 (05) 672-675
    Suche in Google Scholar
  • 15 Ge RJ, Hu RK, Chen H. et al. Progress of Chinese medical diagnosis and treatment on decline in ovarian reserve. Zhonghua Zhongyiyao Zazhi 2020; 35 (01) 322-325
    Suche in Google Scholar
  • 16 He GZ, Yang MC, Xie GZ. et al. Experimental study on effect of BanShi CuLuan ZhuYun decoction on rat model of ovarian hypofunction induced by Tripterygium glycosides. Xinjiang J Tradit Chin Med 2018; 36 (02) 1-4
    Suche in Google Scholar
  • 17 Wu ZZ, Li XM, Liu LY. et al. Growth hormone improves oocyte maturity in patients with polycystic ovary syndrome. J Reprod Med 2019; 28 (11) 1346-1351
    Suche in Google Scholar
  • 18 Zhao L, Diao RY, Cai ZW. et al. Effect of overexpression of miRNA-320 on ovarian function in cisplatin induced premature ovarian failure rats. Lab Anim Sci 2020; 37 (06) 1-6
    Suche in Google Scholar
  • 19 Wang YJ, Xu LW, Liu XF. et al. Advances in research on the etiology of decline in ovarian reserve. J Basic Clin Med 2021; 27 (06) 1047-1050
    Suche in Google Scholar
  • 20 Dong YJ. Observation of the curative effects of Tiaojing decoction combined with estradiol/estradiol dydrogesterone compound tablets. Mod J Integr Tradit Chin West Med 2018; 27 (08) 862-865
    Suche in Google Scholar
  • 21 Wang T, Gao YY, Chen L. et al. Melatonin prevents postovulatory oocyte aging and promotes subsequent embryonic development in the pig. Aging (Albany NY) 2017; 9 (06) 1552-1564
    CrossrefPubMedSuche in Google Scholar
  • 22 Xia JY, Tu YQ, Zuo YH. Therapeutic effect of DHEA on patients with decreased ovarian reserve at different ages. J Reprod Med 2019; 28 (10) 1207-1211
    Suche in Google Scholar
  • 23 Yuan Y, Chen YX, Ma K. et al. Establishment of mouse models of Tripterygium wilfordii polyglycoside-induced early-onset ovarian hypofunction of kidney deficiency and blood stasis syndrome. Zhongguo Zhongyao Zazhi 2019; 44 (09) 1895-1903
    PubMedSuche in Google Scholar
  • 24 Zhao FQ, Xu SQ, Yuan AQ. et al. Effect of Bushen Yangxue decoction combined with estrogen-progesterone sequential therapy on serum sex hormone levels in patients with declined ovarian reserve. Acta Chin Med Pharmacol 2018; 46 (04) 67-69
    Suche in Google Scholar
  • 25 Li G. Exploration of the significance of dehydroepiandrosterone used for decreased ovarian reserve. Zhongguo Xiandai Yaowu Yingyong 2019; 13 (23) 167-168
    Suche in Google Scholar
  • 26 Zhang M, Bener MB, Jiang Z. et al. Mitofusin 2 plays a role in oocyte and follicle development, and is required to maintain ovarian follicular reserve during reproductive aging. Aging (Albany NY) 2019; 11 (12) 3919-3938
    CrossrefPubMedSuche in Google Scholar